Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PIPAC after curative surgery for high-risk colon cancer
2020-000604-11Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and levoleucovorin in colon cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Peritoneal metastasis-free survival. Started Jun 2021; status: active.
02
Drugs
oxaliplatinfluorouracillevoleucovorin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2020-000604-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000604-11.